Corporate news
Dec 06 - United States: in-house manufacturing of Virbac flagship parasiticide
In August, the FDA approved the transfer of production to the Virbac St. Louis site (Missouri) of a parasiticide for dogs acquired by the company at the beginning of 2015. The complexity of the industrial extrusion process required all the skills and attention of the American subsidiary and the Group's Production/Quality teams for nearly three years.
Nov 22 - A better dental care for an optimal dogs’ health
Bad breath is a common complaint of dogs’ owners but it can also be a sign of periodontal or digestive issues that can be painful for the pet. Thanks to a new formula, the C.E.T® VEGGIEDENT® FR3SH™ dental chews tackle the oral causes of bad breath and help to restore the animal's intestinal balance while freshening its breath. Available since 2018 in the United States, Canada, the United Kingdom, France, Spain and Japan, they will gradually be present around the world in 2019.
Nov 13 - Gaïa Index: Virbac ranked again in 2018!
In 2018, Virbac is part of the Gaïa Index, which recommends the 70 French companies with the best ratings in terms of social and environmental responsibility among a panel of 230 firms. Virbac has made a significant improvement of 14 places in the overall ranking compared to 2017.
A company that has always been dedicated to animal health
Founded in 1968 by a French veterinarian, Virbac is an independent pharmaceutical laboratory present in more than 100 countries. The company offers a comprehensive and practical range of products and services covering the majority of species and pathologies.
Join Virbac
Customer driven innovation
Financial public releases
Oct 11 - 2018 third quarter consolidated sales
Revenue grew by +5.5% at constant exchange rates at the end of September 2018
Sep 17 - 2018 half year results
Operating profit up sharply in the first half of 2018
Jul 17 - 2018 second quarter consolidated sales
Revenue grew by +4.3% at constant exchange rates in the second quarter of 2018